Anti-Human CD47 Reference Antibody (STI-6643, RUO)

Catalog No.	HC359236
Brand	abinScience
Host species	Human
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS pH 7.4
Purity	>95% purity as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target	Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
References	1. Thaker YR, et al. A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells. Front Oncol. 2022;12:884196. Published 2022 May 19. [HC359236] 2. Xu S, et al. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. Front Immunol. 2023 May 29;14:1199631. [HC359236]
Purification	Protein A/G purified from cell culture supernatant.
Biological activity	STI-6643 binds to human CD47 with a K d of 76 nM, with lower affinity for cynomolgus (177 nM) and canine (134 nM) CD47 antigens [1]. STI-6643 (25 min) binds dose-dependently to human MDA-MB-231 (EC 50 ~30.0 ug/mL), human RAJI (EC 50 6.64 ug/mL), canine OSCA-40 (EC 50 ~30.0 ug/mL), and canine OSCA-78 (EC 50 ~30.0 ug/mL) cancer cells [1]. STI-6643 (0.09-200 ug/mL; 15 min) dose-dependently blocks the CD47/SIRPα interaction on human CCRF-CEM cells with an IC 50 of 3.65 ug/mL, without reaching saturation at concentrations up to 200 ug/mL [1]. STI-6643 (0.0001-10 ug/mL; 30 min) enhances macrophage-mediated phagocytosis of human RAJI-GFP cells [1]. STI-6643 (1.5625-50 ug/mL) does not exhibit direct tumor cell killing activity on human CCRF-CEM leukemia cells [1]. STI-6643 (100 ug/mL; 25 min) exhibits negligible binding to human (EC 50 = 11.76 ug/mL) and cynomolgus monkey (EC 50 = 20.32 ug/mL) RBCs, with slightly stronger binding to canine RBCs (EC 50 = 5.10 ug/mL) [1]. STI-6643 (0.001-300 ug/mL; 20 h) does not induce hemagglutination of human or cynomolgus monkey RBCs at concentrations up to 300 ug/mL, and exhibits weak, 100-fold less potent hemagglutination activity than Hu5F9 in canine RBCs [1]. STI-6643 (0.001-100 ug/mL; 3 days) preserves human T cell survival and functionality in a superantigen stimulation assay, with minimal impact on IFN-γ secretion [1]. STI-6643 (0.001-500 ug/mL; 6 days) preserves the survival of human CD4+, CD8+, CD19+, and CD56+ immune cells [1]. STI-6643 (2.5-5 ng/mL; 30 min) in combination with Rituximab () enhances macrophage-mediated phagocytosis of human RAJI-GFP cells [1]. STI-6643 (0.1-60 mg/kg; i.v.; 3x/week; 2 consecutive weeks) exhibits potent dose-dependent anti-tumor activity and survival benefits in a mouse disseminated Burkitt's lymphoma xenograft model [1]. STI-6643 (20 mg/kg; i.v.
Endotoxin level	< 10 EU/mg
Expression system	Mammalian cells
Accession	Q08722
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative name	STI-6643, STI6643, STI6643
Clone ID	STI-6643
Note	For research use only. Not suitable for clinical or therapeutic use.